Mammalian Cell Fermentation Technology Market anticipated journey towards the lucrative US$ 68 Billion valuation. At a CAGR of 10% by 2034 | Future Market Insights, Inc. [Yahoo! Finance]
Vaxcyte, Inc. (PCVX)
Company Research
Source: Yahoo! Finance
NEWARK, Del, April 23, 2024 (GLOBE NEWSWIRE) -- The mammalian cell fermentation technology market is estimated to be worth US$ 45.9 billion in 2024 and is projected to be valued at US$ 68 billion by 2034. Between 2024 and 2034, the industry is expected to register a CAGR of The rising prevalence of chronic diseases and the growing aging population worldwide are driving demand for biopharmaceuticals, such as monoclonal antibodies, vaccines, and therapeutic proteins, which are predominantly produced using mammalian cell fermentation technology. The expanding pipeline of biologic drugs, including novel therapeutics and biosimilar, is fuelling demand for mammalian cell fermentation technology for their production. The increasing number of biologic drug approvals and clinical trials further contributes to market growth. Request a Sample of this Report Now! https://www.futuremarketinsights.com/reports/sample/rep-gb-19233 Regulatory agencies worldwide have established clear guidelin
Show less
Read more
Impact Snapshot
Event Time:
PCVX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
PCVX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
PCVX alerts
High impacting Vaxcyte, Inc. news events
Weekly update
A roundup of the hottest topics
PCVX
News
- RS BioTherapeutics Adds Jane Wright-Mitchell, Pharm.D., J.D. to Business Advisory Board [Yahoo! Finance]Yahoo! Finance
- Vaxcyte, Inc. (NASDAQ: PCVX) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $95.00 price target on the stock.MarketBeat
- Phathom Pharma, Rhythm, Vaxcyte most likely takeover targets in pharma - analyst [Seeking Alpha]Seeking Alpha
- Vaxcyte to Present at the 23rd Annual Needham Virtual Healthcare ConferenceGlobeNewswire
- Ford Hutman Media Announces the Promotion of Julia Fuller to Managing Partner [Yahoo! Finance]Yahoo! Finance
PCVX
Earnings
- 11/6/23 - Miss
PCVX
Sec Filings
- 5/3/24 - Form 4
- 5/3/24 - Form 4
- 5/3/24 - Form 4
- PCVX's page on the SEC website